Foslevodopa/Foscarbidopa Overnight Administration Improves Nocturia in Patients with Parkinson's Disease: Evidence from a Real‐World Study
Movement Disorders Clinical Practice · 2026-09 · 13 (9) · 2199-2203
DOI: 10.1002/mdc3.70569 ↗Kurz gefasst
Fachartikel in der Zeitschrift Movement Disorders Clinical Practice, online erschienen am 19.03.2026. Verfasst von Livia Brusa und 13 weiteren Autor:innen. Beteiligte Einrichtung: UOC Neurologia, Movement Disorder Clinic, Ospedale S. Eugenio, Rome, Italy. Hauptthemen laut MEDLINE: Parkinson Disease, Nocturia, Carbidopa, Antiparkinson Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Nocturia is considered as one of the commonest nonmotor symptoms in people with Parkinson's disease ( PD ), highly impacting on quality‐of‐life and health‐related costs.
Objectives
Aim of our real‐world study was to evaluate the impact of Foslevodopa/Foscarbidopa ( LDp / CDp ) subcutaneous infusion ( CSCI ) on nocturia in a group of advanced PD patients.
Methods
Seventy‐eight patients were enrolled in seven Movement Disorders outpatient clinics. International Prostatic Symptoms Scale ( IPSS ) and Nocturia Quality of Life ( NQoL ) questionnaire were administrated before starting LDp / CDp CSCI and after three months of infusion.
Results
In this cohort, LDp / CDp CSCI significantly improved urinary disturbances, nocturia and quality of life. Age and baseline MDS ‐ UPDRS score negatively influenced urinary disturbances and quality of life changes during the treatment, while post‐pre changes of IPSS and LEED showed a negative correlation.
Conclusions
This study supports the utility of the overnight dopaminergic stimulation with LDp / CDp CSCI in controlling overactive bladder.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UOC Neurologia, Movement Disorder Clinic, Ospedale S. Eugenio, Rome, Italy.
- Neurology Unit, Fondazione Policlinico Universitario, A. Gemelli IRCCS, Rome, Italy.
- Department of Neuroscience, Università Cattolica del Sacro Cuore, Rome, Italy.
- Department of System Medicine, University of Tor Vergata, Rome, Italy.
- Department of Behavioral Neurology, Santa Lucia Foundation, Rome, Italy.
- Unit of Neurology, Neurophysiology, Neurobiology and Psychiatry, Department of Medicine, University Campus Bio-Medico of Rome, Rome, Italy.
ORCID-Profile: Massimo Marano, Alessandro Zampogna
Zitieren
APA
Brusa, L., Piano, C., Casula, E. P., Marano, M., Suppa, A., Zampogna, A., Patera, M., Toro, S., Campone, J., Viselli, F., Vacca, L., Alborghetti, M., Stefani, A., & Bove, F. (2026). Foslevodopa/Foscarbidopa Overnight Administration Improves Nocturia in Patients with Parkinson's Disease: Evidence from a Real‐World Study. Movement Disorders Clinical Practice, 13(9), 2199-2203. https://doi.org/10.1002/mdc3.70569
Vancouver
Brusa L, Piano C, Casula EP, Marano M, Suppa A, Zampogna A, et al. Foslevodopa/Foscarbidopa Overnight Administration Improves Nocturia in Patients with Parkinson's Disease: Evidence from a Real‐World Study. Movement Disorders Clinical Practice. 2026;13(9):2199-2203. doi:10.1002/mdc3.70569
BibTeX
@article{Brusa2026,
author = {Brusa, Livia and Piano, Carla and Casula, Elias Paolo and Marano, Massimo and Suppa, Antonio and Zampogna, Alessandro and Patera, Martina and Toro, Stefano and Campone, Jacopo and Viselli, Fabio and Vacca, Laura and Alborghetti, Marika and Stefani, Alessandro and Bove, Francesco},
title = {Foslevodopa/Foscarbidopa Overnight Administration Improves Nocturia in Patients with Parkinson's Disease: Evidence from a Real‐World Study},
journal = {Movement Disorders Clinical Practice},
year = {2026},
volume = {13},
number = {9},
pages = {2199--2203},
doi = {10.1002/mdc3.70569}
}
EUVIMED